The Effects of Topiramate and Flunarizine on Serum Glutamine and of Pontastacus Leptodactylus Neuropeptide Y Levels in Adolescent Rats with a Migraine Model

Abstract

This study aimed to investigate the effects of topiramate and flunarizine on serum glutamine and neuropeptide Y (NPY) levels in adolescent (6 weeks) rats with a migraine model induced by trinitroglycerin (NTG). For this purpose, 48 Wistar albino male rats in the adolescent stage were used. The rats were divided into 6 groups, each consisting of 8 animals. Group 1 (n=8): Healthy control group; no agent was applied. Group 2 (n=8): Migraine group; NTG (10 mg/kg, IP) was administered once daily. Group 3 (n=8): Migraine + Topiramate group; NTG (10 mg/kg, IP) was administered once daily, and topiramate (50 mg) was administered orally twice a day. Group 4 (n=8): Migraine + Flunarizine group; NTG (10 mg/kg, IP) was administered once daily, and flunarizine (5 mg) was administered orally twice a day. Group 5 (n=8): Topiramate group only; topiramate (50 mg) was administered orally twice a day. Group 6 (n=8): Flunarizine group only; flunarizine (5 mg) was administered orally twice a day. All applications were performed for 5 days. In the migraine-induced group, a significant increase in glutamine and NPY levels was observed compared to the control group. However, in the topiramate and flunarizine groups (grup 5 and 6), no significant differences were detected in these levels compared to the control group. The NTG application was found to be suitable for creating a migraine model, but to observe better clinical findings, an increase in both dose and duration may be necessary. It was concluded that migraine results in brain damage, and as an indicator of damage, both NPY and glutaminase levels may increase. Glutaminase might be slightly more sensitive than NPY in detecting brain damage in migraine, but this sensitivity should be further compared in more experimental studies